PK Accelerator Bundled Solution Accelerates Pharmacokinetic Analysis and Reporting MOUNTAIN VIEW, Calif., June 24 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading...
Talk Will Cover the Use of Pharsight Software for In-Vitro / In-Vivo Correlation Modeling in Drug Development MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Pharsight(R) Corporation...
Dr. Farkad Ezzet Will Present on the Strategic Value of Literature Modeling to Assess Disease Progression and Drug Attributes in Clinical Development MOUNTAIN VIEW, Calif., June 17...
Dr. Laurent Claret Will Present Case Studies on the Value of Drug-Disease Modeling to Predict Efficacy and Survival Benefits of Anticancer Agents MOUNTAIN VIEW, Calif., June 12...
Dr. Robert Leary Will Discuss Computational Methods for Model Evaluation; Dr. Mike Dunlavey Will Present Simplified Programming Approaches of Population Model User Interfaces MOUNTAIN VIEW...
Dr. Helen Kastrissios Will Present on Communicating the Value of Pharmacodynamic Modeling in Clinical Drug Development MOUNTAIN VIEW, Calif., May 27 /PRNewswire-FirstCall/ -- Pharsight...
Second Annual European Meeting to be Held In Paris MOUNTAIN VIEW, Calif., May 23 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of software, strategic...
Fourth Quarter Revenue Highest in Company History; Full Year Revenue Up 13% MOUNTAIN VIEW, Calif., May 8 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of...
Dr. Bill Poland Will Present on the Strategic Use of Incorporating Adherence Data into Clinical Trial Predictions of Antiviral Therapies MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/...
John Murphy Appointed as New Senior Vice President of Consulting Services MOUNTAIN VIEW, Calif., April 29 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.